Kythera Newsroom

Current Release

KYTHERA Biopharmaceuticals To Present at the Goldman Sachs US Emerging / SMID Cap Growth Conference

November 14, 2014

Westlake Village, Calif., November 14, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York.

Event:        Goldman Sachs US Emerging / SMID Cap Growth Conference

Date:          Thursday, November 20, 2014

Time:        1:40 p.m. ET

A live webcast will be available under the Investors section of the Company’s website at www.kytherabiopharma.com. The presentation will be archived on the website and will be available for at least 14 days.

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is currently in late-stage clinical development for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA submitted its New Drug Application for ATX-101 in May 2014, which the FDA has determined will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.

Investor Contact
Heather Rowe
Director, Investor Relations
hrowe@kytherabiopharma.com

Permalink